What is the most appropriate initial cognitive screening test for a 72-year-old woman with three months of worsening memory loss, unsafe behaviors, hypertension treated with metoprolol, hypothyroidism treated with levothyroxine, normal vital signs, and inability to recall three words?

Mini-Cog or Montreal Cognitive Assessment (MoCA)

For this 72-year-old woman presenting with clear signs and symptoms of cognitive impairment (worsening forgetfulness, unsafe behaviors, inability to recall three words), the most appropriate next step is formal cognitive screening with either the Mini-Cog (3 minutes) or Montreal Cognitive Assessment (10 minutes), not routine screening but rather diagnostic evaluation of symptomatic cognitive impairment.

Key Clinical Context

This patient is not a candidate for routine screening—she has overt symptoms and safety concerns that mandate immediate cognitive assessment. The USPSTF guideline explicitly distinguishes between universal screening (which has insufficient evidence) and evaluation of patients with recognized signs or symptoms, which is appropriate clinical practice 1.

Why This Matters

The patient demonstrates:

• Three months of progressive memory loss (subacute timeframe)
• Safety-threatening behaviors (leaving stove on, door open)
• Failed three-word recall during examination
• Lives alone with escalating risk

These are not subtle findings—they represent clear cognitive impairment requiring formal assessment, not screening.

Recommended Screening Tests

First-Tier Options:

Mini-Cog (3 minutes):

• Sensitivity 91%, specificity 86% for dementia 2
• Free, brief, minimal training required
• Less affected by education/language barriers 3
• Combines three-word recall with clock drawing
• Best for rapid assessment when time is limited 3

Montreal Cognitive Assessment (MoCA):

• Sensitivity 89%, specificity 75% for mild cognitive impairment 2
• Superior for detecting early/mild impairment 2, 4
• Takes approximately 10 minutes
• More comprehensive cognitive domain assessment
• Publicly available

Alternative Options:

Mini-Mental State Examination (MMSE):

• Sensitivity 81%, specificity 89% for dementia 2
• Most studied instrument (102 studies, >10,000 patients) 2
• Major limitation: proprietary, requires payment 1, 4
• Takes 10 minutes
• Less sensitive for mild cognitive impairment

Addenbrooke's Cognitive Examination-Revised (ACE-R) or Mini-Addenbrooke (M-ACE):

• ACE-R: Sensitivity 92%, specificity 89% 2
• M-ACE: AUC 0.867, best balance of accuracy and brevity 5
• Excellent for MCI detection 5
• Takes longer than Mini-Cog but more comprehensive

Clinical Algorithm

1. Immediate assessment: Use Mini-Cog if time-constrained (3 minutes) or MoCA if more time available (10 minutes)
2. If screen positive: Proceed to comprehensive neuropsychological testing and workup for reversible causes
3. Safety assessment: Given living alone with unsafe behaviors, immediate caregiver involvement or supervision needed regardless of test results

Critical Medication Review

Metoprolol and levothyroxine are unlikely culprits:

• Beta-blockers can cause CNS effects, but this patient has been stable on metoprolol 6
• Hypothyroidism itself causes cognitive impairment, but she's treated with levothyroxine 7
• However: Verify TSH is therapeutic—untreated or undertreated hypothyroidism mimics dementia

Common Pitfalls to Avoid

1. Don't delay formal testing because "screening evidence is insufficient"—that applies to asymptomatic patients, not this symptomatic presentation 1

2. Don't use Memory Impairment Screen (MIS) as first-line—sensitivity only 43% for dementia 8, AUC 0.672 5

3. Don't skip workup for reversible causes: TSH, B12, metabolic panel, neuroimaging are essential next steps after positive screen

4. Don't assume this is normal aging—three months of progressive decline with functional impairment is pathologic

5. Address safety immediately—cognitive testing doesn't eliminate the acute risk of living alone with impaired judgment

Evidence Quality Note

The guideline evidence 1 clearly states that while routine screening lacks evidence, evaluation of symptomatic patients is appropriate clinical practice. The research evidence 5, 2, 4, 8, 3 provides robust comparative data on test performance, with the most recent 2024 study 5 showing M-ACE and ACE-III superiority for MCI detection, though Mini-Cog and MoCA remain excellent practical choices given their widespread availability and strong performance characteristics.